

MEDIA RELEASE

VivaZome and BIA Separations to collaborate on downstream technology for exosome purification.

VivaZome presenting at 2021 Biotech Showcase

21 December 2020; Melbourne Australia and Ajdovščina, Slovenia: VivaZome Therapeutics Pty Ltd (“VivaZome”) and BIA Separations (“BIA”) – a part of the life science group Sartorius – today announced that they have entered into a collaborative research project for exosome purification. BIA’s unique CIM (Convective Interaction Media) monolith chromatography technology will be used to purify exosomes from VivaZome’s cell cultures, with the aim of developing a high-efficiency downstream purification and concentration process for exosome production.

Under the collaborative arrangement, VivaZome will provide exosome-rich, cell culture supernatant produced by VivaZome’s preferred cell type. BIA’s expert Bioprocessing Team, located in Ajdovščina, Slovenia, will use the VivaZome material to evaluate and optimise the monolith technology with the objective of demonstrating high purification capability, efficient removal of contaminants, fast flow rates and scale-ability. VivaZome and BIA will each contribute their expertise in exosome characterisation and analytics.

VivaZome’s Chief Executive Officer, Dr David Haylock, stated: “VivaZome is delighted to enter into this international collaboration. BIA brings high-level expertise and unique technology to the table. The monolith technology has been shown to work well with exosomes and we look forward to building on that experience. BIA and VivaZome recognise that the development of a high-efficiency downstream separation and concentration process is key to the manufacture of therapeutic exosomes and to realising their therapeutic potential.”

BIA’s Chief Scientific Officer, Pete Gagnon added: “Monoliths permit high flow rates that translate to short process time, and high exosome capacity that translates to low material consumption. Those features enable the high productivity needed to put exosome manufacturing on a strong economical foundation. BIA’s parallel development of exosome-customized surface chemistries and fast analytical methods meanwhile provides the additional elements needed to purify clinical-quality exosomes.”

In further news, VivaZome advises that CEO David Haylock is presenting at Biotech Showcase 2021, which will be delivered digitally on January 11-15, 2021. In its thirteenth consecutive year, the Biotech Showcase is a USA-based investor conference devoted to providing private and micro-mid-cap biotechnology companies an opportunity to present to, and meet with, biopharmaceutical and life science company executives, investors in private and public companies, sector analysts, bankers and industry professionals. The VivaZome presentation is available now as on-demand content on the Biotech Showcase platform and is expected to draw significant interest. Go to <http://events.ebdgroup.com/bts/core/presenting-companies2021.php?speakerSearch=vivazome>.

For further information, contact:

<u>VivaZome Therapeutics Pty Ltd</u> Dr David Haylock, CEO David.haylock@vivazome.com Phone: +61 (0) 439 617 657	<u>BIA Separations</u> Ales Strancar, managing director ales.strancar@biaseparations.com Phone: +386 596 99500
---------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



About VivaZome Therapeutics Pty Ltd

VivaZome Therapeutics Pty Ltd (ABN 59 602 230 964) is a privately-held Australian biotech company, with headquarters at the La Trobe University Technology Enterprise Centre. VivaZome was formed to develop and commercialise exosome-based therapies for debilitating and/or life-threatening disorders, with an initial focus on ischaemia, fibrotic disease and neurological disorders.

VivaZome is developing new technologies and generating intellectual property and proprietary materials that are applicable generically to exosome therapies. They will underpin the Company's development of specific exosome types for its target indications.

The VivaZome team has extensive expertise in the development and commercialisation of biological therapies, together with a wide network of expert contacts in the Australian and global biotech community.

VivaZome acknowledges the support of the Department of Industry, Science, Energy and Resources through the CRC-P program, and the work of its CRC-P partners, La Trobe University and SeerPharma Pty Ltd.

For more information, please visit www.vivazome.com.

About BIA Separations

BIA Separations is part of the life science group Sartorius and develops and manufactures market-leading products for purification and analysis of large biomolecules, such as viruses, plasmids and mRNA, which are used in cell and gene therapies and other advanced therapies. Founded in 1998, BIA Separations has invented and commercialized the unique CIM (convective interaction media) monolith chromatography technology. In addition, it offers analytical technologies for process monitoring and optimization. BIA's technology for manufacturing scale purification is already used in production of the first commercialized advanced therapeutics and the company also has a strong presence with such novel drug candidates in the clinical pipeline.

For more information, please visit www.biaseparations.com.

About Sartorius

The Sartorius Group is a leading international partner of the life science research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group's Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In fiscal 2019, the company earned sales revenue of some 1.83 billion euros. At the end of 2019, more than 9,000 people were employed at the Group's approximately 60 manufacturing and sales sites, serving customers around the globe.